long intergenic non-protein coding RNA 683Genealiases: []
Q-omics provides the consensus-scored LINC00683 profile across patient tissues and cancer cell-line models. LINC00683 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LINC00683 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, LINC00683 RNA expression shows 12,720 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, LIHC, and TGCT as cancer lineages where LINC00683 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00683 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00683 survival associations across molecular data types. LINC00683 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00683 RNA expression–survival associations across cancer types. High LINC00683 expression shows unfavorable associations in COAD and BLCA, but favorable associations in PAAD, LUAD, UCEC and ACC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LINC00683 RNA expression.
This table summarizes LINC00683 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00683. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00683 shows lower tumor expression in LIHC, KIRC, THCA, KICH, BLCA and PRAD. The LIHC box plot shows higher LINC00683 RNA expression in normal versus tumor tissue (log2 FC = −0.145, t-test p < 0.001).
This table shows molecular features associated with LINC00683 in patient tissues and cancer cell lines. In patient samples, LINC00683 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
